Single dose oral Azithromycin versus injection Benzathine benzylpenicillin in the treatment of yaws- A randomized noninferiority trial in some endemi

Single dose oral Azithromycin versus injection Benzathine benzylpenicillin in the treatment of yaws- A randomized noninferiority trial in some endemic communities in Ghana

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201306000520103

Enrollment

420

Registered

2013-03-13

Start date

2011-02-28

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Musculoskeletal Diseases Skin and Connective Tissue Diseases Yaws

Interventions

Oral Azithromycin

Injection Benzathine Benzylpenicillin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ¿ The subject aged 1-15 years ¿ The guardian/child has signed/thumb printed written informed consent The subject has clinical diagnosis of primary/secondary yaws The subject has laboratory confirmation of yaws i.e., reactive TPHA and RPR test of at least 1:4 The subject/guardian is willing to make participant available for follow up.

Exclusion criteria

Exclusion criteria: ¿ The subject does not have reactive serologic test for yaws The subject has late yaws The subject has known suspected allergy to Penicillin and/or macrolide antibiotics The subject has been on a broad spectrum antibiotic in preceding 30 days The subject is judged by investigator to be unlikely to participate in the study follow

Design outcomes

Primary

Measure	Time frame
Cure at 6 months	—

Secondary

Measure	Time frame
Clincal cure ;serological cure;serological cure	—

Countries

Ghana

Contacts

Public ContactPatrick Nsiiri Agana

National Yaws Elimination Program Manager

agana.nsiire@gmail.com233 244 292170

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026